<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05070546</url>
  </required_header>
  <id_info>
    <org_study_id>CR109038</org_study_id>
    <secondary_id>2021-001909-77</secondary_id>
    <secondary_id>VAC18193RSV3006</secondary_id>
    <nct_id>NCT05070546</nct_id>
  </id_info>
  <brief_title>A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF&#xD;
      based vaccine in adults 18 to 59 years of age who are healthy or at risk for severe&#xD;
      Respiratory Syncytial Virus (RSV) disease, compared to adults 65 years and above.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RSV is an important cause of serious respiratory infections in adults aged 60 years and&#xD;
      older, immunocompromised individuals, and those with underlying chronic cardiopulmonary&#xD;
      conditions. The current study assess the safety and immunogenicity of the RSV vaccine in&#xD;
      adults 18 to 59 years of age, including those who are at risk for severe RSV disease. The&#xD;
      study comprises screening (pre-vaccination) and vaccination for each participant on Day 1,&#xD;
      and a 6- month safety and immunogenicity follow-up period. The study duration will be up to 6&#xD;
      months per participant. Assessments like immunogenicity (such as humoral and cellular immune&#xD;
      responses), safety (such as monitoring of AEs, physical examinations, and vital signs) and&#xD;
      reactogenicity will be performed in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Anticipated">June 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 9, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Solicited Local Adverse Events (AEs) After Vaccination</measure>
    <time_frame>7 days after vaccination (Day 8)</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant administered an investigational or non-investigational medicinal product. An AE does not necessarily have a causal relationship with the treatment. Solicited local AEs are pre-defined local (at the injection site) AEs for which participants will be specifically questioned and which will be noted by participants in their diary for 7 days post-vaccination (day of vaccination and the subsequent 7 days). Solicited local AEs are injection site pain/tenderness, erythema and swelling at the vaccination site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Solicited Systemic AEs After Vaccination</measure>
    <time_frame>7 days after vaccination (Day 8)</time_frame>
    <description>Solicited systemic AEs (fatigue, headache, myalgia, and nausea) will be noted in the participant diary on a daily basis for 7 days post-vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Unsolicited AEs After Vaccination</measure>
    <time_frame>28 days after vaccination (Day 29)</time_frame>
    <description>Unsolicited AEs will include all AEs for which the participant is not specifically questioned in the participant diary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>6 months after vaccination (up to Day 183)</time_frame>
    <description>A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>6 months after vaccination (up to Day 183)</time_frame>
    <description>Number of participants with AESIs will be reported. Thrombosis with thrombocytopenia syndrome is considered to be an AESI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing Antibody Titers Against RSV A2 Strain as Measured by Virus Neutralization Assay (VNA)</measure>
    <time_frame>14 days after vaccination (Day 15)</time_frame>
    <description>Neutralizing antibody titers against respiratory syncytial virus (RSV) A2 strain as measured by VNA will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroresponse Rate After Vaccination As Determined by VNA A2</measure>
    <time_frame>Baseline to 14 days after vaccination (Day 15)</time_frame>
    <description>Percentage of seroresponders determined by VNA A2 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RSV A Pre-F Protein Binding Antibodies by ELISA</measure>
    <time_frame>14 days after vaccination (Day 15)</time_frame>
    <description>Antibodies binding to RSV A F protein in pre-fusion form will be assessed by ELISA.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1113</enrollment>
  <condition>Respiratory Syncytial Virus Infection Prevention</condition>
  <arm_group>
    <arm_group_label>Cohort (C)1 Group (G)1: Healthy Adults, 18-59 Years (Respiratory Syncytial Virus [RSV] vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intramuscular (IM) injection of study vaccine on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 G2: Healthy Adults, 18-59 Years (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single IM injection of matching placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G3: High Risk Adult, 18-59 Years (RSV Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IM injection of study vaccine on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 G4: High Risk Adult, 18-59 Years (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single IM injection of matching placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 G5: Adults, 65 Years and Older (RSV Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IM injection of study vaccine on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 G6: Adults, 65 Years and Older (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single IM injection of matching placebo on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.RSV.preF-based Vaccine</intervention_name>
    <description>Participants will receive a single IM injection of an RSV vaccine.</description>
    <arm_group_label>C2 G3: High Risk Adult, 18-59 Years (RSV Vaccine)</arm_group_label>
    <arm_group_label>C3 G5: Adults, 65 Years and Older (RSV Vaccine)</arm_group_label>
    <arm_group_label>Cohort (C)1 Group (G)1: Healthy Adults, 18-59 Years (Respiratory Syncytial Virus [RSV] vaccine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive a single IM injection of matching placebo.</description>
    <arm_group_label>C1 G2: Healthy Adults, 18-59 Years (Placebo)</arm_group_label>
    <arm_group_label>C2 G4: High Risk Adult, 18-59 Years (Placebo)</arm_group_label>
    <arm_group_label>C3 G6: Adults, 65 Years and Older (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be of a) non child bearing potential or b) of child bearing&#xD;
             potential and practicing an acceptable and effective of contraception&#xD;
&#xD;
          -  All participants of childbearing potential must: have a negative highly sensitive&#xD;
             urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening; and&#xD;
             have a negative highly sensitive urine beta-hCG pregnancy test immediately prior to&#xD;
             each study vaccination (if screening and vaccination are not performed on the same&#xD;
             day) Cohorts 1 and 2&#xD;
&#xD;
          -  Participant is aged 18 to 59 years (inclusive) on the day of signing the informed&#xD;
             consent form (ICF) and expected to be available for the duration of the study Cohort 2&#xD;
&#xD;
          -  Has an existing chronic heart or lung condition, without hospitalizations or major&#xD;
             medication class change (that is, new or stopped medications) within 30 days prior to&#xD;
             screening, meeting the following criteria; a) cardiac disease: at least Class II&#xD;
             symptoms per New York Heart Association classification or similar guidelines according&#xD;
             to local practice, b) pulmonary disease: activity-restricting symptoms or use of&#xD;
             long-term medications Cohort 3&#xD;
&#xD;
          -  Participant is aged 65 years or older on the day of signing the ICF and expected to be&#xD;
             available for the duration of the study&#xD;
&#xD;
          -  Participant may have underlying illnesses such as hypertension, congestive heart&#xD;
             failure, chronic obstructive pulmonary disease (COPD), type 2 diabetes,&#xD;
             hyperlipoproteinemia, or hypothyroidism, as long as their symptoms and signs are&#xD;
             stable at the time of vaccination, and these conditions receive routine follow-up by&#xD;
             the participant's healthcare provider&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected allergy or history of anaphylaxis or other serious adverse&#xD;
             reactions to vaccines or their excipients (including specifically the excipients of&#xD;
             the study vaccine)&#xD;
&#xD;
          -  Abnormal function of immune system due to a clinical condition or treatment&#xD;
&#xD;
          -  History of thrombosis with thrombocytopenia syndrome (TTS) or heparin-induced&#xD;
             thrombocytopenia and thrombosis (HITT).&#xD;
&#xD;
          -  Participant received or plans to receive: (a) licensed live attenuated vaccines -&#xD;
             within 28 days before or after planned administration of study vaccine; and (b) other&#xD;
             licensed (not live) vaccines - within 14 days before or after planned administration&#xD;
             of study vaccine&#xD;
&#xD;
          -  Received an respiratory syncytial virus (RSV) vaccine in a previous RSV vaccine study&#xD;
&#xD;
          -  History of acute polyneuropathy (example, Guillain-Barre syndrome) or chronic&#xD;
             idiopathic demyelinating polyneuropathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alliance for Multispeciality Research</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Institute of South Florida Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, an AMR Company</name>
      <address>
        <city>El Dorado</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc.</name>
      <address>
        <city>Yukon</city>
        <state>Oklahoma</state>
        <zip>73099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispeciality Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Anima</name>
      <address>
        <city>Alken</city>
        <zip>3570</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>C.H.U. St Pierre / Maladies Infectieuses</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Private Practice RESPISOM Namur</name>
      <address>
        <city>Namur</city>
        <zip>5101</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin-Mitte GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Dresden GmbH</name>
      <address>
        <city>Dresden</city>
        <zip>01069</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research HamburggmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zentrum fuer klinische Forschung</name>
      <address>
        <city>Koeln</city>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SIBAmed GmbH &amp; Co. KG</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Schwerin GmbH</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Virgen de La Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>FISABIO</name>
      <address>
        <city>Valencia</city>
        <zip>46020</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>ProbarE i Lund AB</name>
      <address>
        <city>Lund</city>
        <zip>22222</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinSmart Sweden AB</name>
      <address>
        <city>Solna</city>
        <zip>171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ProbarE i Stockholm AB</name>
      <address>
        <city>Stockholm</city>
        <zip>113 29</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Studieenheten Akademiskt Specialistcentrum Stockholm</name>
      <address>
        <city>Stockholm</city>
        <zip>11361</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR109038</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

